Hannes Manell

Hannes Manell

Auto-generated profile, based on publicly available information

Hannes Manell

Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2019 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
HMHannes Manell
Hannes Manell
HKHjalti Kristinsson
Hjalti Kristinsson
JKJoel Kullberg
Joel Kullberg
SUSarojini Jayantha Kumari Ubhayasekera
Sarojini Jayantha Kumari Ubhayasekera
KMKatharina Mörwald
Katharina Mörwald
PBPeter Bergsten
Peter Bergsten

29 May 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RSRasmus Stenlid
Rasmus Stenlid
HMHannes Manell
Hannes Manell
MHMaria Halldin
Maria Halldin
JKJoel Kullberg
Joel Kullberg
HAHåkan Ahlström
Håkan Ahlström
AFAnders Forslund
Anders Forslund
Context Dipeptidyl peptidase 4 (DPP-4) metabolizes glucagon-like peptide-1 (GLP-1), and increased DPP4 levels are associated with obesity and visceral adiposity in adults. Objective Investigating DPP-4 levels in adolescents and their association with (1) circulating intact GLP-1 levels and glucose tolerance; (2) body mass index (BMI); and (3) visceral, subcutaneous, and liver fat compartments. Design Cross-sectional study, July 2012 to April 2015. Setting Pediatric obesity clinic, Uppsala University Hospital. Patients and Participants Children and adolescents with obesity (n = 59) and lean controls (n = 21) aged 8 to 18 years. Main Outcome Measures BMI SD score, fasting plasma concentrations of DPP-4, total and intact GLP-1, fasting and oral glucose tolerance test (OGTT) concentrations of glucose, and visceral adipose tissue (VAT) and subcutaneous adipose tissue volumes and liver fat fraction. Results Plasma DPP-4 levels decreased with age in both obese (41 ng/mL per year) and lean subjects (48 ng/mL per year). Plasma DPP-4 levels were higher in males in both the obesity and lean groups. With adjustments for age and sex, plasma DPP-4 level was negatively associated with intact GLP-1 at fasting (β = −12.3; 95% CI: −22.9, −1.8) and during OGTT (β = −12.1; 95% CI: −22.5, −1.7). No associations were found between DPP-4 and plasma glucose levels measured at fasting or after a 2-hour OGTT. Plasma DPP-4 level was 19% higher in obese subjects. Among adipose tissue compartments, the strongest association was with VAT (β = 0.05; 95% CI: −0.02, 0.12). Conclusions In adolescents, high plasma DPP-4 concentrations were associated with low proportions of intact GLP-1, high BMI, young age, and male sex. The observed associations are compatible with increased metabolism of GLP-1 in childhood obesity.

1 November 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
RSRasmus Stenlid
Rasmus Stenlid
SCSara Y Cerenius
Sara Y Cerenius
QWQuan Wen
Quan Wen
BABanu Aydin
Banu Aydin
HMHannes Manell
Hannes Manell
PBPeter Bergsten
Peter Bergsten
Background: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT.Subjects and Measurements: This study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses.Results: Exenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT.Conclusion: Weekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity.Clinical trial registration: clinicaltrials.gov, identifier NCT02794402

9 July 2019 in Pediatric Obesity
Verified
Journal Article
Open access
PDF file
ELElin Lundström
Elin Lundström
JLJoy Ljungberg
Joy Ljungberg
JAJonathan Andersson
Jonathan Andersson
HMHannes Manell
Hannes Manell
RSRobin Strand
Robin Strand
JKJoel Kullberg
Joel Kullberg
Summary: Background: Despite therapeutic potential against obesity and diabetes, the associations of brown adipose tissue (BAT) with glucose metabolism in young humans are relatively unexplored.Objectives: To investigate possible associations between magnetic resonance imaging (MRI) estimates of BAT and glucose metabolism, whilst considering sex, age, and adiposity, in adolescents with normal and overweight/obese phenotypes.Methods: In 143 subjects (10‐20 years), MRI estimates of BAT were assessed as cervical‐supraclavicular adipose tissue (sBAT) fat fraction (FF) and from water‐fat MRI. FF and of neighbouring subcutaneous adipose tissue (SAT) were also assessed. Adiposity was estimated with a standardized body mass index, the waist‐to‐height ratio, and abdominal visceral and subcutaneous adipose tissue volumes. Glucose metabolism was represented by the 2h plasma glucose concentration, the Matsuda index, the homeostatic model assessment of insulin resistance, and the oral disposition index; obtained from oral glucose tolerance tests.Results: sBAT FF and correlated positively with adiposity before and after adjustment for sex and age. sBAT FF, but not , correlated with 2h glucose and Matsuda index, also after adjustment for sex, age, and adiposity. The association with 2h glucose persisted after additional adjustment for SAT FF.Conclusions: The association between sBAT FF and 2h glucose, observed independently of sex, age, adiposity, and SAT FF, indicates a role for BAT in glucose metabolism, which potentially could influence the risk of developing diabetes. The lacking association with sBAT might be due to FF being a superior biomarker for BAT and/or to methodological limitations in the quantification.

5 November 2024 in Pediatric Research
Verified
Journal Article
Open access
PDF file
BTBeata Tersander
Beata Tersander
RORoger Olsson
Roger Olsson
BABanu K. Aydin
Banu K. Aydin
RSRasmus Stenlid
Rasmus Stenlid
ICIris Ciba
Iris Ciba
HMHannes Manell
Hannes Manell
Background: Studies on the associations between obesity-related subclinical hypothyroidism with basal metabolic rate and risk factors of cardiovascular disease in children and adolescents are scarce. Methods: Retrospective cohort study of children with obesity (n = 294) from the Uppsala Longitudinal Study of Childhood Obesity cohort. Differences in basal metabolic rate quantified by indirect calorimetry, and the cardiovascular risk factors; body mass index, blood lipids, fasting and 2 h oral glucose tolerance test glucose, glycated haemoglobin and insulin resistance, between subjects with and without subclinical hypothyroidism were investigated. The associations of baseline thyroid stimulating hormone (TSH) and ΔTSH with change in cardiovascular risk factors over time were assessed. Results: Subjects with subclinical hypothyroidism had elevated triacylglycerides but no alterations in basal metabolic rate or other measured cardiovascular risk factors. ΔTSH was positively associated with Δtriacylglycerides, Δtotal-cholesterol and ΔLDL-cholesterol, independently of age, sex, Δbody mass index and ΔT4. In the subclinical hypothyroidism group, 92% of individuals normalised their TSH 0.9–2.9 years later. Conclusions: Children with obesity and subclinical hypothyroidism did not have an altered basal metabolic rate but elevated triacylglycerides. During the follow-up period, TSH changed in parallel with several blood lipids. Elevated TSH often normalised without pharmaceutical intervention within 3 years. Impact: The present study found that subclinical hypothyroidism in paediatric obesity is related to elevated triglycerides. The present study found that subclinical hypothyroidism is not associated to basal metabolic rate in paediatric obesity. TSH change over time correlated with the change in triglycerides and LDL and total cholesterol. Among subjects with subclinical hypothyroidism at baseline 92% normalised without pharmaceutical intervention within 3 years. This research adds to the knowledge of the longitudinal, natural course of elevated TSH in paediatric obesity which is expected to help to make informed decisions regarding follow-up and evaluation of this patient group.

5 July 2024 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
HMHannes Manell
Hannes Manell
NTNikolaos Tsolakis
Nikolaos Tsolakis
CJChrister Janson
Christer Janson
AMAndrei Malinovschi
Andrei Malinovschi
KAKjell Alving
Kjell Alving
Background: The immunological mechanisms behind the clinical association between asthma and obesity in adolescence are not fully understood. This study aimed to find new plasma protein biomarkers associated specifically with coincident asthma and obesity in adolescents.Methods: This was a cross‐sectional study in children and adolescents 10–19 years old (N = 390). Relative plasma concentrations of 113 protein biomarkers related to inflammation and immune response were determined by proximity extension assay (Target 96; Olink, Uppsala, Sweden). Differences in protein concentrations between healthy controls (n = 84), subjects with asthma (n = 138), subjects with obesity (n = 107), and subjects with both asthma and obesity (AO; n = 58) were analyzed by ANCOVA, adjusting for age and sex, and in a separate model adjusting also for the sum of specific IgE antibody concentrations to a mix of food allergens (fx5) and aeroallergens (Phadiatop). Proteins elevated in the AO group but not in the obesity or asthma groups were considered specifically elevated in asthma and obesity.Results: Five proteins were elevated specifically in the AO group compared to controls (here sorted from largest to smallest effect of asthma and obesity combined): CCL8, IL‐33, IL‐17C, FGF‐23, and CLEC7A. The effects of adjusting also for specific IgE were small but IL‐33, IL‐17C, and FGF‐23 were no longer statistically significant.Conclusion: We identified several new potential plasma biomarkers specifically elevated in coincident asthma and obesity in adolescents. Four of the proteins, CCL8, IL‐33, IL‐17C, and CLEC7A, have previously been associated with viral mucosal host defense and Th17 cell differentiation.